Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Adenocarcinoma

Adenocarcinoma of Lung

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Adenocarcinoma

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Carboplatin

Pemetrexed

Tislelizumab

Immunomodulating Agents

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antineoplastic Agents, Immunological

Folinic Acid

Folate

Vitamin B9

intravenous injection :Tislelizumab + pemetrexed + platinum Q3W 2-4 cycles

200 mg ,intravenous injection ,Q3W 2-4 cycles

500 mg/m2,intravenous injection ,Q3W 2-4 cycles

pemetrexed

60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles

cis-platemum

AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles

or carboplatin

Henry liang, Dr

hengrui liang

jun liu

Jun liu, Professor

Neoadjuvant EGFR TKI therapy targeting EGFR mutation has some problems failure to fulfill clinical requirements such as low MPR rate, tissue fibrosis and other major surgical impacts and unmet clinical needs.This study hypothesized that Tisleizumab combined with chemotherapy in the neoadjuvant treatment of stage II-IIIA non-squamous NSCLC with EGFR-mutant PD-L1 expression ≥1% could significantly improve the pathological response rate after neoadjuvant therapy, improve the surgical complete resection rate, reduce perioperative complications and do not increase the surgical difficulty.In this study, biomarker analysis is going to explore the possible direction of neoadjuvant therapy population screening, and to explore a possible method for the efficacy and safety of neoadjuvant immunotherapy in clinical stage II-IIIA non-squamous non-small cell lung cancer with EGFR mutation and expression of PD-L1.

A Single-arm Exploratory Study of Neoadjuvant Therapy

Neoadjuvant Tislelizumab and Platinum-Based Doublet Chemotherapy in Stage II-IIIB EGFR-Mutated Lung Adenocarcinoma With PD-L1 Positive Expression -- A Phase II Study (DuoVitality)"

MPR of surgical specimens from patients who were operable after neoadjuvant therapy was evaluated

To evaluate objective response rate (ORR) in neoadjuvant treatment

pCR of surgical specimens from patients who were operable after neoadjuvant therapy was evaluated

Proportion of patients whose pathologic lymph node stage was reduced to N1/N0 by baseline radiographic assessment of N2 or N1

To evaluate the safety profile(Number of Participants with Adverse Events)

evaluate the interval time from the completation of last neoadjuvant therapy to surgery

explore different surgery manner rate after neoadjuvant

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Single-arm Exploratory Study of Neoadjuvant Therapy	NCT05527808	Lung Adenocarci...	Tislelizumab pemetrexed cis-platemum or carboplatin	18 Years - 75 Years	Guangzhou Institute of Respiratory Disease
A Single-arm Exploratory Study of Neoadjuvant Therapy	NCT05527808	Lung Adenocarci...	Tislelizumab pemetrexed cis-platemum or carboplatin	18 Years - 75 Years	Guangzhou Institute of Respiratory Disease

Spots Global Cancer Trial Database for or carboplatin